Loading
Mannatech Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Rameson Tyler, was filed 10 Sept 2024.
Mannatech Inc: what insiders have been doing
Every trade that managers of Mannatech Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Flower Mound, United States. It was founded in 1994. 6 insiders have disclosed 6 filings since 22 October 2025.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Insider buying of Mannatech Inc has been absent for the past year. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. For comparison, the SEC allows two business days to file a Form 4.
Compared with its exchange (3,171 companies, median 24 filings), a count of 6 filings is below the norm. Since 2016, the database holds 25 purchases and 22 sales by insiders of the company. The 10-K for the year ended 31 December 2025 shows 108.0 m USD of revenue and -15.2 m USD of net income.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
152
Thresholds
n/a
Buy Volume
€488,163
25 ops. · all time
Sell Volume
€590,716
22 ops. · all time
Since the insiders bought
- +6.8%Entry US$7.60 · Close at T+365 US$8.12
- +106.9%Entry US$17.87 · Close at T+365 US$36.98
- +99.9%Entry US$16.76 · Close at T+365 US$33.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,955 of 26,286 companies
27.8
score / 100
Value5
Quality50
FCF yld-26%
Earn yld-92%
EV/EBITDA·
ROE·
Gross mgn75%
Net mgn-14%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$8.54
Analyst consensus
Income statement
RevenueUS$108M
Gross profitUS$81M75% margin
EBITDA-US$1.4M-1% margin
Net income-US$15.2M-6.9% margin
Valuation
P/Book1.6x
Beta0.76
Balance sheet & cash
Market capUS$16.5M
Total debtUS$7.4M
Free Cash Flow-US$4.3M
Profitability & ownership
ROE-1490.1%
ROA5.5%
% insiders59.3%
% institutions15.1%
Last declaration on 6 January 2026
Declarations152 total
4,790 shares@ US$8.3510.7% of flowCommon stock, par value $0.0001SEC:0001437749-26-000572:0
4,790 shares@ US$8.3526.0% of flowCommon stock, par value $0.0001SEC:0001437749-26-000568:0
4,790 shares@ US$8.3514.9% of flowCommon stock, par value $0.0001SEC:0001437749-26-000566:0
4,790 shares@ US$8.3516.5% of flowCommon stock, par value $0.0001SEC:0001437749-26-000563:0
4,790 shares@ US$8.3511.5% of flowCommon stock, par value $0.0001SEC:0001437749-26-000553:0
4,790 shares@ US$8.357.4% of flowCommon stock, par value $0.0001SEC:0001437749-26-000570:0
2,686 shares@ US$14.898.4% of flowCommon Stock Par Value $0.0001 Per ShareSEC:0001056358-25-000010:0
2,686 shares@ US$14.8913.1% of flowCommon Stock, par value $0.0001 per shareSEC:0001056358-25-000004:0
2,686 shares@ US$14.8918.8% of flowCommon Stock Par Value $0.0001 Per ShareSEC:0001056358-25-000013:0
2,686 shares@ US$14.8912.2% of flowCommon Stock Par Value $0.0001 Per ShareSEC:0001056358-25-000011:0
2,686 shares@ US$14.8916.9% of flowCommon Stock Par Value $0.0001 Per ShareSEC:0001056358-25-000012:0
2,686 shares@ US$14.8929.5% of flowCommon stock, par value $0.0001SEC:0001056358-25-000002:0
16,288 shares@ US$7.7536.0% of flowCommon Stock Par Value $0.0001 Per ShareSEC:0001056358-24-000072:0
16,288 shares@ US$7.7538.7% of flowCommon Stock, par value $0.0001 per shareSEC:0001056358-24-000070:0
Canonical exit: 8 Dec 2024 (T+90)
1,012 shares@ US$7.602.2% of flowCommon Stock Par Value $0.0001 Per ShareSEC:0001056358-24-000046:0
8,187 shares@ US$9.1686.5% of flowCommon Stock Par Value $0.0001 Per ShareSEC:0001056358-24-000014:0
4,932 shares@ US$8.117.9% of flowCommon Stock Par Value $0.0001 Per ShareSEC:0001056358-24-000008:0
4,932 shares@ US$8.1111.4% of flowCommon Stock Par Value $0.0001 Per ShareSEC:0001056358-24-000006:0
4,932 shares@ US$8.1117.6% of flowCommon Stock Par Value $0.0001 Per ShareSEC:0001056358-24-000010:0
4,932 shares@ US$8.1112.2% of flowCommon Stock, par value $0.0001 per shareSEC:0001056358-24-000007:0
4,932 shares@ US$8.1127.7% of flowCommon stock, par value $0.0001SEC:0001056358-24-000009:0
1,000 shares@ US$12.406.3% of flowCommon Stock, par value $0.0001 per shareSEC:0001056358-23-000061:0
1,217 shares@ US$12.824.5% of flowCommon Stock Par Value $0.0001 Per ShareSEC:0001056358-23-000059:0
115 shares@ US$12.620.4% of flowCommon Stock, par value $0.0001 per shareSEC:0001056358-23-000051:1
154 shares@ US$12.891.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001056358-23-000051:0
25 of 152 declarations
About Mannatech Inc
Mannatech, Incorporated (ticker: MTEX) is a U.S.-listed small-cap company traded on the NASDAQ Capital Market in the United States, operating in the health and wellness industry. Founded in 1993 and headquartered in Flower Mound, Texas, the company develops and markets proprietary nutritional supplements, topical skin-care and anti-aging products, and weight-management and fitness products. Its business model is rooted in direct selling and an independent distributor network, placing it closer to a network-marketing wellness company than to a traditional pharmaceutical manufacturer. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1056358/000105635825000018/mtex-20241231.htm?utm_source=openai))
Historically, Mannatech has positioned itself as a pioneer of “glyconutrition,” a plant-based nutrition concept centered on ingredients intended to support cellular nutrition. The company highlights product families such as Ambrotose and a broader portfolio aimed at nutrition, immune health, skincare, and weight management. This gives Mannatech a distinct brand identity, but it also means the company is highly dependent on consumer trust, the perceived credibility of its product claims, and the effectiveness of its distributor ecosystem. ([us.mannatech.com](https://us.mannatech.com/products/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Mannatech operates in a crowded, fragmented market where supplement brands, beauty-focused wellness companies, and direct-selling peers all compete for recurring customers and active distributors. The company’s moat is not based on scale or cutting-edge IP, but on brand loyalty, product differentiation, and network engagement. Management discloses sales across three geographic regions: the Americas, EMEA, and Asia/Pacific, showing an international footprint despite the company’s relatively modest size. Its headquarters and corporate base remain firmly anchored in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1056358/000105635825000018/mtex-20241231.htm?utm_source=openai))
Recent developments suggest continued operational consolidation and disciplined portfolio management. In the second quarter of 2024, Mannatech liquidated its Sweden entity, and its investor-relations materials show ongoing SEC reporting and a 2025 quarterly reporting cycle. The company’s recent filings and insider-activity coverage reinforce that MTEX is closely watched by microcap investors and market participants following SEC Form 4 disclosures. For investors, Mannatech is best viewed as a niche U.S. wellness platform with a long operating history, a recognizable product set, and an international sales base, but also meaningful exposure to regulatory, reputational, and channel-execution risks common in the dietary supplement sector. ([ir.mannatech.com](https://ir.mannatech.com/overview/default.aspx?utm_source=openai))
